Five-year results of a controlled study of BCG immunotherapy after surgical resection in bronchogenic carcinoma.

Millar, James R.; Roscoe, P.; Pearce, S J; Ludgate, Susanne N.; Horne, N. W.

doi:10.1136/thx.37.1.57

Cited by 16 publications

(1 citation statement)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This induced inflammation not only kills the tumor, probably by activating the innate immune system, but also leads to sustained immune responses by activating the local antigen-presenting cells. BCG was tried to treat lung cancer but failed to show any responses [ 165 – 167 ]. Two other therapies such as using Corynebacterium parvum [ 168 ] and Mycobacterium vaccae [ 169 ] have been tried with lung cancers.…”

Section: Immunotherapy Against Lung Cancers and Opportunimentioning

confidence: 99%

Lung Cancer: A Classic Example of Tumor Escape and Progression While Providing Opportunities for Immunological Intervention

Jadus

Natividad

Mai

et al. 2012

Clinical and Developmental Immunology

View full text Add to dashboard Cite

Lung cancers remain one of the most common and deadly cancers in the world today (12.5% of newly diagnosed cancers) despite current advances in chemo- and radiation therapies. Often, by the time these tumors are diagnosed, they have already metastasized. These tumors demonstrate the classic hallmarks of cancer in that they have advanced defensive strategies allowing them to escape various standard oncological treatments. Immunotherapy is making inroads towards effectively treating other fatal cancers, such as melanoma, glioblastoma multiforme, and castrate-resistant prostate cancers. This paper will cover the escape mechanisms of bronchogenic lung cancer that must be overcome before they can be successfully treated. We also review the history of immunotherapy directed towards lung cancers.

show abstract

Section: Immunotherapy Against Lung Cancers and Opportunimentioning

confidence: 99%

Lung Cancer: A Classic Example of Tumor Escape and Progression While Providing Opportunities for Immunological Intervention

Jadus

Natividad

Mai

et al. 2012

Clinical and Developmental Immunology

View full text Add to dashboard Cite

show abstract

Review: Perioperative therapy for locoregional nonsmall-cell lung cancer

Takita

1996

J. Surg. Oncol.

View full text Add to dashboard Cite

Surgical therapy remains the treatment of choice for resectable nonsmall‐cell lung cancer (NSCLC). However, the 5‐year survival results of surgical therapy is 40–70%, which is far from acceptable. In this report, past results of perioperative therapies were reviewed to identify the future direction of effort in improving the therapy of NSCLC. Two perioperative modes of treatment that may possibly improve postsurgical survival were identified, i.e., neoadjuvant chemotherapy for resectable NSCLC and postoperative specific active immunotherapy. © 1996 Wiley‐Liss, Inc.

show abstract

Adjuvant immunotherapy with nonviablemycobacterium smegmatis in resected primary lung carcinoma a randomized clinical trial of 219 patients

Decroix

Chastang

Fichet

et al. 1984

Cancer

View full text Add to dashboard Cite

Two hundred and nineteen patients with resected lung carcinoma were randomized 3 weeks after surgery between two treatment arms: a control group (110 cases) and an immunotherapy group (109 cases). The immunostimulant was a nonviable saprophytic mycobacterium, M. smegmatis, given monthly by subcutaneous injection in four sites. The two groups were equivalent in terms of prognostic factors, including a nonsignificant difference favoring the control group based on the N (node) classification. This interim analysis was carried out on June 1, 1981. Treatment comparison by the log‐rank test did not show any significant differences between these two groups in regards to disease‐free interval and overall survival. There was no significant difference between the two groups after stratification of the comparison according to the N classification or adjustment with a subset of eight prognostic parameters through the Cox model. The initially expected difference (20% 1‐year survival) will probably not be achieved, given these interim results, but patients will continue to be treated and followed‐up according to the protocol as to allow further evaluation of this nonspecific immunotherapy.

show abstract

Five-year results of a controlled study of BCG immunotherapy after surgical resection in bronchogenic carcinoma.

Abstract: Ninety-two patients with histologically confirmed bronchogenic carcinoma treated by surgical resection of the tumour were subsequently given immunotherapy with BCG (Glaxo). The patients were randomly allocated into three groups. Twenty-nine patients received multipuncture BCG (50 to

Cited by 16 publications

References 9 publications

Lung Cancer: A Classic Example of Tumor Escape and Progression While Providing Opportunities for Immunological Intervention

Lung Cancer: A Classic Example of Tumor Escape and Progression While Providing Opportunities for Immunological Intervention

Review: Perioperative therapy for locoregional nonsmall-cell lung cancer

Adjuvant immunotherapy with nonviablemycobacterium smegmatis in resected primary lung carcinoma a randomized clinical trial of 219 patients

Contact Info

Product

Resources

About